SCHEMBL16359253

SCHEMBL16359253

NC(=O)[C@H](CO)NC(=O)CCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
MMP2 P08253 2/20 0.52
MMP8 P22894 2/20 0.52
MMP12 P39900 2/20 0.52
MMP13 P45452 1/20 0.52
HDAC1 Q13547 3/20 0.50
MAPT P10636 2/20 0.50
GAA P10253 2/20 0.50
HTT P42858 1/20 0.50
GLS O94925 1/20 0.50
PARP1 P09874 1/20 0.49
PARP3 Q9Y6F1 1/20 0.49
ALDH1A1 P00352 1/20 0.49
ITGB3 P05106 1/20 0.47
ITGA2B P08514 1/20 0.47
PIN1 Q13526 1/20 0.47
CTSG P08311 1/20 0.47
CMA1 P23946 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24533878 0.88 MMP2 (0.58) HDAC2HDAC8HDAC6MMP2MMP8
SCHEMBL24533867 0.88 MMP2 (0.58) HDAC2HDAC8HDAC6MMP2MMP8
SCHEMBL6138237 0.87 HDAC2 (0.56) HDAC2HDAC8HDAC6HDAC1MAPT
SCHEMBL6240137 0.86 MMP2 (0.54) HDAC2HDAC8HDAC6MMP2MMP8
SCHEMBL16908006 0.86 HDAC2 (0.51) HDAC2HDAC8HDAC6MMP2MMP8
SCHEMBL30687362 0.86 HDAC2 (0.51) HDAC2HDAC8HDAC6MMP2MMP8
SCHEMBL29734985 0.85 MMP2 (0.59) HDAC2HDAC8HDAC6MMP2MMP8
SCHEMBL24725085 0.85 KISS1R (0.55) MMP8IL1RNERAP2ERAP1LNPEP
SCHEMBL16908173 0.84 MMP2 (0.49) HDAC2HDAC8HDAC6MMP2MMP8
SCHEMBL14122510 0.83 MMP12 (0.66) MMP2MMP8MMP12MMP13IL1RN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023028338-A2 MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2023-03-02 WO disclosed
WO-2023009554-A1 METHODS TO REDUCE ADVERSE EFFECTS OF GENE OR BIOLOGICS THERAPY AVILAR THERAPEUTICS, INC. (US) 2023-02-02 WO disclosed
WO-2022235699-A2 POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2022-11-10 WO disclosed
WO-2010053548-A2 PTHR1 RECEPTOR COMPOUNDS ANCHOR THERAPEUTICS, INC. (US) 2010-05-14 WO disclosed